跳至主要内容
临床试验/2026-526160-21-00
2026-526160-21-00招募中4 期

Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up

Rigshospitalet1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2026年5月1日最近更新:
干预措施

试验速览

阶段
4 期
状态
招募中
入组人数
1,000
试验地点
1

研究概览

简要总结

The follow-up study has one primary aim: To measure the level of specific immunity, measured as level of measles neutralising antibodies by plaque-reduction neutralisation test 1-3 years after routine MMR vaccination at 4 years of age and compare this level between the two original MMR groups: The one, which received an early MMR and the one, which received placebo in the trial .

入排标准

年龄范围
0 years 至 17 years(0-17 Years)
接受健康志愿者

入选标准

  • Participation in the original MMR trial

排除标准

  • Immune-deficiency (primary or acquired) or –suppression, and/or intake of immune modulating medicine (including high doses of corticosteroids), thrombocytopenia or any coagulation disorder, blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems. Children who received blood or plasma transfusions, or administration of human immune serum globulin within the last 3 months will be excluded.

研究组 & 干预措施

MEASLES, COMBINATIONS WITH MUMPS AND RUBELLA, LIVE ATTENUATED

Test

干预措施: MEASLES, COMBINATIONS WITH MUMPS AND RUBELLA, LIVE ATTENUATED (Drug)

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Dorthe Maria Vittrup

Scientific

Rigshospitalet

研究点 (1)

Loading locations...

相似试验